Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : PT-00114
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I/ Phase II
Sponsor : Phytanix Bio
Deal Size : Undisclosed
Deal Type : Merger
Protagenic Therapeutics Receives $3.1 Million from Recent Warrant Activity
Details : The combined entity, to be called Phytanix, Inc, will bring together two pipelines focused on stress-related and CNS disorders such as PT-00114, is being evaluated for Treatment-Resistant Depression.
Product Name : PT-00114
Product Type : Peptide
Upfront Cash : Undisclosed
May 21, 2025
Lead Product(s) : PT-00114
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I/ Phase II
Sponsor : Phytanix Bio
Deal Size : Undisclosed
Deal Type : Merger
Lead Product(s) : PT-00114
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I/ Phase II
Sponsor : Phytanix Bio
Deal Size : Undisclosed
Deal Type : Merger
Protagenic & Phytanix Merge to Form Biotech With Six Neuroactive Drug Programs
Details : The combined entity, to be called Phytanix, Inc, will bring together two pipelines focused on stress-related and CNS disorders such as PT-00114, is being evaluated for Treatment-Resistant Depression.
Product Name : PT-00114
Product Type : Peptide
Upfront Cash : Undisclosed
May 19, 2025
Lead Product(s) : PT-00114
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I/ Phase II
Sponsor : Phytanix Bio
Deal Size : Undisclosed
Deal Type : Merger
Lead Product(s) : PT00114
Therapeutic Area : Psychiatry/Psychology
Study Phase : IND Enabling
Sponsor : Undisclosed
Deal Size : $2.0 million
Deal Type : Financing
Protagenic Therapeutics Completes $2.0 Million Convertible Note Financing
Details : The capital will be used to complete the last remaining components of the Company’s investigational New Drug (IND) filing with the FDA for its lead drug compound, PT00114, known scientifically as teneurin C-terminal associated peptide (TCAP).
Product Name : PT00114
Product Type : Peptide
Upfront Cash : Undisclosed
August 09, 2020
Lead Product(s) : PT00114
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : IND Enabling
Sponsor : Undisclosed
Deal Size : $2.0 million
Deal Type : Financing